United States Biotechnology & Medical Research

Biomea Fusion Inc (BMEA)

Track

Track

Recent insider activity at Biomea Fusion Inc shows multiple purchase transactions occurring between November 28 and December 11, 2025. Key personnel, including the interim CEO and other stakeholders, acquired shares during this period. These acquisitions represent the most significant recent movements, reflecting internal confidence without indicating broader market trends or future performance expectations.
Ticker: BMEA Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Biomea Fusion Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.5
Erdtmann Rainer M See Remarks Executive Director
Transaction date
Purchase
Price
15.10
Quantity 99,724 -36.6%
Value US$1,641,200
3.1
Hitchcock Michael J.M. Interim CEO Executive Director
Transaction date
Purchase
Price
117.51
Quantity 56,759 +31.9%
Value US$920,214
3.5
Erdtmann Rainer M See Remarks Executive Director
Transaction date
Purchase
Price
358.71
Quantity 11,146 +38.6%
Value US$3,148,876
3.5
Erdtmann Rainer M See Remarks Executive Director
Transaction date
Purchase
Price
1.10
Quantity 40,000 +6.2%
Value US$44,052
3.1
Hitchcock Michael J.M. Non-Executive Director
Transaction date
Purchase
Price
10.06
Quantity 10,000 +200.0%
Value US$100,600
2.6
Valle Franco Chief Financial Officer Officer
Transaction date
Purchase
Price
4.43
Quantity 12,509 +41.7%
Value US$55,361
3.5
A2A Pharmaceuticals, Inc. 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
32.13
Quantity 1,500,000
Value US$48,195,000
3.5
A2A Pharmaceuticals, Inc. Stakeholder Large shareholder
Transaction date
Proposed sale
Price
30.00
Quantity 400,000
Value US$12,000,000
3.5
A2A Pharmaceuticals, Inc. 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
27.75
Quantity 200,000
Value US$5,550,000
2.2
Chen Bihua Non-Executive Director Large shareholder
Transaction date
Purchase
Price
30.00
Quantity 400,000 +12.6%
Value US$12,000,000
3.1
Hitchcock Michael J.M. Non-Executive Director
Transaction date
Purchase
Price
7.93
Quantity 5,000 +inf%
Value US$39,650
2.6
Valle Franco Chief Financial Officer Officer
Transaction date
Purchase
Price
7.63
Quantity 4,100 +30.8%
Value US$31,286
3.5
A2A Pharmaceuticals, Inc. Large shareholder
Transaction date
Sale
Price
11.21
Quantity 34,658 -0.8%
Value US$388,516
3.5
A2A Pharmaceuticals, Inc. Large shareholder
Transaction date
Sale
Price
11.76
Quantity 34,658 -0.8%
Value US$407,578
2.6
Valle Franco Chief Financial Officer Officer
Transaction date
Purchase
Price
8.68
Quantity 10,000 +inf%
Value US$86,767
2.2
Chen Bihua Non-Executive Director
Transaction date
Purchase
Price
17.00
Quantity 900,000 +39.6%
Value US$15,300,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-15 2025-12-11 B Purchase
3.5
Erdtmann Rainer M

See Remarks

Executive Director
99,724 -36.6%
15.10
US$1,641,200 		99,724 -36.6% 15.10 US$1,641,200
2025-12-04 2025-12-02 B Purchase
3.1
Hitchcock Michael J.M.

Interim CEO

Executive Director
56,759 +31.9%
117.51
US$920,214 		56,759 +31.9% 117.51 US$920,214
2025-12-02 2025-12-01 B Purchase
3.5
Erdtmann Rainer M

See Remarks

Executive Director
11,146 +38.6%
358.71
US$3,148,876 		11,146 +38.6% 358.71 US$3,148,876
2025-12-02 2025-11-28 B Purchase
3.5
Erdtmann Rainer M

See Remarks

Executive Director
40,000 +6.2%
1.10
US$44,052 		40,000 +6.2% 1.10 US$44,052
2024-10-01 2024-09-30 B Purchase
3.1
Hitchcock Michael J.M.
Non-Executive Director
10,000 +200.0%
10.06
US$100,600 		10,000 +200.0% 10.06 US$100,600
2024-06-12 2024-06-11 B Purchase
2.6
Valle Franco

Chief Financial Officer

Officer
12,509 +41.7%
4.43
US$55,361 		12,509 +41.7% 4.43 US$55,361
2023-06-02 2023-06-01 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
50,000 -1.4%
34.56
US$1,728,165 		50,000 -1.4% 34.56 US$1,728,165
2023-06-02 2023-05-31 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
75,000 -2.1%
33.81
US$2,535,750 		75,000 -2.1% 33.81 US$2,535,750
2023-05-19 2023-05-19 PrS Proposed sale
3.5
A2A Pharmaceuticals, Inc.

10% Stockholder

Large shareholder
1,500,000
32.13
US$48,195,000 		1,500,000 32.13 US$48,195,000
2023-05-17 2023-05-12 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
25,000 -0.7%
33.84
US$846,000 		25,000 -0.7% 33.84 US$846,000
2023-05-10 2023-05-09 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
150,000 -3.9%
34.50
US$5,175,720 		150,000 -3.9% 34.50 US$5,175,720
2023-05-10 2023-05-08 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
100,000 -2.6%
33.99
US$3,399,310 		100,000 -2.6% 33.99 US$3,399,310
2023-04-27 2023-04-27 PrS Proposed sale
3.5
A2A Pharmaceuticals, Inc.

Stakeholder

Large shareholder
400,000
30.00
US$12,000,000 		400,000 30.00 US$12,000,000
2023-04-26 2023-04-20 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
200,000 -4.9%
29.12
US$5,823,760 		200,000 -4.9% 29.12 US$5,823,760
2023-04-20 2023-04-20 PrS Proposed sale
3.5
A2A Pharmaceuticals, Inc.

10% Stockholder

Large shareholder
200,000
27.75
US$5,550,000 		200,000 27.75 US$5,550,000
2023-04-03 2023-03-30 B Purchase
2.2
Chen Bihua
Non-Executive Director Large shareholder
400,000 +12.6%
30.00
US$12,000,000 		400,000 +12.6% 30.00 US$12,000,000
2022-11-16 2022-11-14 B Purchase
3.1
Hitchcock Michael J.M.
Non-Executive Director
5,000 +inf%
7.93
US$39,650 		5,000 +inf% 7.93 US$39,650
2022-11-14 2022-11-11 B Purchase
2.6
Valle Franco

Chief Financial Officer

Officer
4,100 +30.8%
7.63
US$31,286 		4,100 +30.8% 7.63 US$31,286
2022-07-25 2022-07-21 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
34,658 -0.8%
11.21
US$388,516 		34,658 -0.8% 11.21 US$388,516
2022-06-28 2022-06-24 S Sale
3.5
A2A Pharmaceuticals, Inc.
Large shareholder
34,658 -0.8%
11.76
US$407,578 		34,658 -0.8% 11.76 US$407,578
2022-01-18 2022-01-14 B Purchase
2.6
Valle Franco

Chief Financial Officer

Officer
10,000 +inf%
8.68
US$86,767 		10,000 +inf% 8.68 US$86,767
2021-04-22 2021-04-20 B Purchase
2.2
Chen Bihua
Non-Executive Director
900,000 +39.6%
17.00
US$15,300,000 		900,000 +39.6% 17.00 US$15,300,000
Explore more

More insider trading research around Biomea Fusion Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America